No Data
No Data
China Grants Marketing Approval to Luye Pharma's Anti-Schizophrenia Tablets
China's medical products administrator granted marketing approval to Luye Pharma Group's (HKG:2186) Meibirui antipsychotic drug for schizophrenia, according to a Tuesday filing with the Hong Kong Stoc
Luye Pharma (02186): Mebipuri (Paliperidone Palmitate Injection) has been approved for listing in China.
Luye Pharma (02186) announced that its independently-developed second-generation long-acting antipsychotic injection, Mebiray (Paliperidone Palmitate Injection), has been approved by the National Medical Products Administration of the People's Republic of China for the treatment of acute and maintenance phases of schizophrenia.
Express News | Luye Pharma - Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China by Nmpa
Sinopec SSC (01033) signed a turnkey fixed-price contract with Saudi Aramco for the MGS Phase III Pipeline Project Groups 6 and 7 domestic procurement and construction, with a total investment of approximately RMB 7.956 billion.
Luye Pharma (02186) submitted a new drug application for Lisinopril Transdermal Patch (2 times/W) in Japan; Kingkey Fin Int (01468) signed a memorandum of understanding with PRIME on potential cooperation in developing and promoting solar power plants, energy and environmental technology solutions.
Express News | Luye Pharma - Towa Pharmaceutical Filed Nda in Japan for Rivastigmine Twice Weekly Transdermal Patch
Private Companies Who Have a Significant Stake Must Be Disappointed Along With Institutions After Luye Pharma Group Ltd.'s (HKG:2186) Market Cap Dropped by HK$940m
Key Insights Significant control over Luye Pharma Group by private companies implies that the general public has more power to influence management and governance-related decisions 56% of the busine
No Data